Jeremy Bender, Day One Biopharmaceuticals CEO

Day One goes to the mar­ket for $150M as biotech kicks off NDA re­quest for pe­di­atric brain can­cer drug

Day One Bio­phar­ma­ceu­ti­cals will of­fer up more than 11.5 mil­lion shares to nab $150 mil­lion in gross pro­ceeds af­ter the biotech last month start­ed a rolling sub­mis­sion for its pe­di­atric brain can­cer drug, which had a fresh da­ta drop at last week­end’s AS­CO.

The Bris­bane, CA-based drug de­vel­op­er will al­so give in­vestors a chance to buy an­oth­er 1.73 mil­lion shares at the price of $13 apiece, which would send pro­ceeds up an­oth­er $22.5 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.